Trial Profile
A Single-dose Cross-over Study to Assess Direct and Indirect Effects of Dapagliflozin on Pancreatic Alpha and Beta Cells in Patients With Type 2 Diabetes
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Apr 2022
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary) ; Saxagliptin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 17 Aug 2018 Results published in the Journal of Clinical Endocrinology and Metabolism
- 15 Sep 2017 Results presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
- 09 Dec 2016 Status changed from recruiting to completed.